Pfizer shows promise in vaccine trial - Full show on CBS All Access

Marco Green
July 4, 2020

"I was glad to see Pfizer put up their phase 1 trial data today".

How the study was conducted: For the initial study, 45 participants ages 18 to 55 were randomly assigned to either receive a certain dose of the vaccine or placebo. "However, what we can say at this point is there is a viable candidate based on immunogenicity and early tolerability safety data".

The vaccine is among 150 now under evaluation worldwide.

The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said.

"These first trial results show that the vaccine yields immune activity and causes a strong immune response", said BioNTech's co-founder and Chief Executive Officer Ugur Sahin. "We look forward to providing further data updates on BNT162b1".

An ongoing collaborative Phase1/2 clinical trial in the U.S. and involving 45 participants aged between 18 and 55 have received either 10, 30, or 100 microgram doses of the drug BNT162b1 vaccine or a placebo over 21 days.

The GMC data from this cohort was reported to be eight and 46.3 times higher than the GMC in a panel of participants who had contracted the virus.

Those who received the vaccine, whether one dose or two, had more antibodies in their blood after 21 days than people who had recovered from coronavirus infections, the companies said.

According to Pfizer, local reactions and systemic events after injection with 10 µg and 30 µg of BNT162b1 were "dose-dependent, generally mild to moderate, and transient". The group that got two injections with two different doses of the experimental vaccine produced the highest level of antibodies. The companies noted they didn't know how long the immune responses would last, or what level of immunity humans need for protection from the virus. That trial may involve up to 30 000 healthy participants and is anticipated to begin in late July 2020, if regulatory approval to proceed is received.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER